Pfizer completed acquisition of ion-channel-drug discovery company Icagen ($6.00/share, ~$56M total). Note: small deal but strategically notable platform acquisition for Pfizer's Neusentis pain unit. Below $250M threshold but a notable platform deal.
Did it work? Outcome assessment
Strategic verdict
Partially Achieved
Financial impact
Neutral
Pipeline outcome
Mixed
Assessment window: 5yr post-close.
Key facts
AnnouncedSep 20, 2011
ClosedOct 27, 2011
Deal value$56M
Deal typeAcquisition/Merger
Therapeutic areaPain, sensory disorders, regenerative medicine
IndicationsPain, sensory disorders, regenerative medicine
Key assetsIon-channel small-molecule drug discovery platform; pain and sensory disorder candidates